Abstract
1 Xamoterol (Corwin, Carwin, Corwil, Xamtol, ICI 118,587) is a β1-adrenoceptor partial agonist which, unlike full β-adrenoceptor agonists, does not down-regulate β-adrenoceptors in the rat ventricle during chronic administration.
2 Improvements in myocardial performance have been demonstrated following acute administration of xamoterol to patients with mild or moderate heart failure, and these are sustained during at least 1 year of continued treatment.
3 Exercise duration is increased by xamoterol in patients with left ventricular dysfunction and benefit is still apparent after at least 1 year of therapy.
4 Despite sustained cardiac stimulation, xamoterol does not appear to affect adversely mortality in patients with mild or moderate heart failure.
5 Few adverse events directly attributable to xamoterol were reported during 3 month efficacy studies in more than 600 patients, and the laboratory safety profile over 1 year of treatment is good.
6 Xamoterol is a promising, well-tolerated addition to established therapies for chronic mild or moderate heart failure.
Keywords: xamoterol, heart failure
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Colucci W. S., Alexander R. W., Williams G. H., Rude R. E., Holman B. L., Konstam M. A., Wynne J., Mudge G. H., Jr, Braunwald E. Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med. 1981 Jul 23;305(4):185–190. doi: 10.1056/NEJM198107233050402. [DOI] [PubMed] [Google Scholar]
- Cook N., Richardson A., Barnett D. B. Comparison of the beta 1 selective affinity of prenalterol and corwin demonstrated by radioligand binding. Eur J Pharmacol. 1984 Mar 2;98(3-4):407–412. doi: 10.1016/0014-2999(84)90289-9. [DOI] [PubMed] [Google Scholar]
- Detry J. M., Decoster P. M., Brasseur L. A. Hemodynamic effects of Corwin (ICI 118,587), a new cardioselective beta-adenoceptor partial agonist. Eur Heart J. 1983 Aug;4(8):584–591. doi: 10.1093/oxfordjournals.eurheartj.a061524. [DOI] [PubMed] [Google Scholar]
- Glover D. R., Wathen C. G., Murray R. G., Petch M. C., Muir A. L., Littler W. A. Are the clinical benefits of oral prenalterol in ischaemic heart failure due to beta blockade? A six month randomised double blind comparison with placebo. Br Heart J. 1985 Feb;53(2):208–215. doi: 10.1136/hrt.53.2.208. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Guyatt G. H. The treatment of heart failure. A methodological review of the literature. Drugs. 1986 Dec;32(6):538–568. doi: 10.2165/00003495-198632060-00004. [DOI] [PubMed] [Google Scholar]
- Lambertz H., Meyer J., Erbel R. Long-term hemodynamic effects of prenalterol in patients with severe congestive heart failure. Circulation. 1984 Feb;69(2):298–305. doi: 10.1161/01.cir.69.2.298. [DOI] [PubMed] [Google Scholar]
- Lammers J. W., Müller M. E., Folgering H. T., van Herwaarden C. L. A comparative study on the ventilatory and haemodynamic effects of xamoterol and atenolol in asthmatic patients. Br J Clin Pharmacol. 1986 Nov;22(5):595–602. doi: 10.1111/j.1365-2125.1986.tb02940.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Löfdahl C. G., Svedmyr N. Effects of xamoterol (ICI 118,587) in asthmatic patients. Br J Clin Pharmacol. 1984 Oct;18(4):597–601. doi: 10.1111/j.1365-2125.1984.tb02510.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Poole-Wilson P. A. The future role of inotropic drugs. Drugs. 1986;32 (Suppl 5):27–32. doi: 10.2165/00003495-198600325-00004. [DOI] [PubMed] [Google Scholar]
- Rousseau M. F., Cheron P., Vincent M. F., Pouleur H., Lavenne F. Intérêt du xamotérol dans l'insuffisance cardiaque modérée d'étiologie ischémique. Ann Cardiol Angeiol (Paris) 1984 May-Jun;33(4):215–218. [PubMed] [Google Scholar]
- Rousseau M. F., Pouleur H., Vincent M. F. Effects of a cardioselective beta 1 partial agonist (corwin) on left ventricular function and myocardial metabolism in patients with previous myocardial infarction. Am J Cardiol. 1983 May 1;51(8):1267–1274. doi: 10.1016/0002-9149(83)90297-7. [DOI] [PubMed] [Google Scholar]
- Sørensen E. V., Faergeman O., Day M. A., Snow H. M. Long-term efficacy of xamoterol (a beta 1-adrenoceptor partial agonist) in patients with mild to moderate heart failure. Br J Clin Pharmacol. 1989;28 (Suppl 1):86S–88S. doi: 10.1111/j.1365-2125.1989.tb03583.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Weber K. T., Andrews V., Janicki J. S. Cardiotonic agents in the management of chronic cardiac failure. Am Heart J. 1982 Apr;103(4 Pt 2):639–649. doi: 10.1016/0002-8703(82)90469-0. [DOI] [PubMed] [Google Scholar]